$38.76
0.96% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Ionis Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation

Ionis Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
70%
Hold
26%
Sell
4%

Ionis Pharmaceuticals, Inc. Price Target

Target Price $61.32
Price $38.76
Potential
Number of Estimates 22
22 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. target price is $61.32. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 27 analysts: 19 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Ionis Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 787.65 621.46
34.10% 21.10%
EBITDA Margin -42.05% -84.40%
36.35% 100.70%
Net Margin -47.46% -84.33%
0.48% 77.68%

22 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2024 . The average Ionis Pharmaceuticals, Inc. sales estimate is

$621m
Unlock
. This is
23.65% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$680m 16.46%
Unlock
, the lowest is
$578m 28.99%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $788m 34.10%
2024
$621m 21.10%
Unlock
2025
$734m 18.07%
Unlock
2026
$953m 29.90%
Unlock
2027
$1.3b 41.04%
Unlock
2028
$1.8b 35.42%
Unlock

7 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2024. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is

$-525m
Unlock
. This is
53.18% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-454m 32.68%
Unlock
, the lowest is
$-570m 66.46%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-331m 14.65%
2024
$-525m 58.36%
Unlock
2025
$-599m 14.21%
Unlock
2026
$-386m 35.53%
Unlock

EBITDA Margin

2023 -42.05% 36.35%
2024
-84.40% 100.70%
Unlock
2025
-81.64% 3.27%
Unlock
2026
-40.52% 50.37%
Unlock

23 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Ionis Pharmaceuticals, Inc. net profit estimate is

$-524m
Unlock
. This is
41.85% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-364m 1.58%
Unlock
, the lowest is
$-602m 62.84%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-374m 34.74%
2024
$-524m 40.18%
Unlock
2025
$-500m 4.57%
Unlock
2026
$-363m 27.34%
Unlock
2027
$-146m 59.94%
Unlock
2028
$133m 191.06%
Unlock

Net Margin

2023 -47.46% 0.48%
2024
-84.33% 77.68%
Unlock
2025
-68.16% 19.17%
Unlock
2026
-38.13% 44.06%
Unlock
2027
-10.83% 71.60%
Unlock
2028
7.28% 167.22%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.56 -3.59
34.74% 40.23%
P/E negative
EV/Sales 9.67

23 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.59
Unlock
. This is
41.90% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.49 1.58%
Unlock
, the lowest is
$-4.12 62.85%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.56 34.74%
2024
$-3.59 40.23%
Unlock
2025
$-3.42 4.74%
Unlock
2026
$-2.49 27.19%
Unlock
2027
$-1.00 59.84%
Unlock
2028
$0.91 191.00%
Unlock

P/E ratio

Current -15.34 24.62%
2024
-10.80 29.60%
Unlock
2025
-11.32 4.81%
Unlock
2026
-15.58 37.63%
Unlock
2027
-38.88 149.55%
Unlock
2028
42.70 209.83%
Unlock

Based on analysts' sales estimates for 2024, the Ionis Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.39 21.47%
2024
9.67 30.89%
Unlock
2025
8.19 15.30%
Unlock
2026
6.31 23.02%
Unlock
2027
4.47 29.10%
Unlock
2028
3.30 26.16%
Unlock

P/S ratio

Current 7.51 24.98%
2024
9.84 30.97%
Unlock
2025
8.33 15.30%
Unlock
2026
6.41 23.02%
Unlock
2027
4.55 29.10%
Unlock
2028
3.36 26.16%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today